Hartmut Timmermann

KEYWORDS Asthma Dupilumab Lung function Asthma control Biomarkers Clinical remission Real-world study Get full text access Log in, subscribe or purchase for full access. REFERENCES 1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2025. Updated May 2025. https://ginasthma.org/2025-gina-strategy-report/ (accessed 25 June 2025). 2. Lommatzsch, M. ∙ Brusselle, G.G. ∙ Canonica, G.W. ... Disease-modifying anti-asthmatic drugs Lancet. 2022; 399(10335):1664-1668 3.

Back to Journals » Journal of Asthma and Allergy » Volume 17 Authors Milger K , Koschel D, Skowasch D , Timmermann H, Schmidt O, Bergmann KC, Neurohr C, Lindner R, Heck S, Virchow JC Received 29 May 2024 Accepted for publication 21 October 2024 Published 1 November 2024 Volume 2024:17 Pages 1093—1101 DOI https://doi.org/10.2147/JAA.S480380 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Professor David Price Katrin...

Introduction Disease severity in asthma has been replaced by the level of asthma control in asthma recommendations over the years.1,2 According to the Global Initiative for Asthma (GINA) guidelines, patients with “severe asthma” require treatment at step 4 or 5 in order for their condition to be “controlled”.